Understanding monogenic Parkinson's disease at a global scale

Johanna Junker, MD*[1,2], Lara M. Lange, MD*[1,2], Eva-Juliane Vollstedt, MD[1], Karisha Roopnarain, MD[3], Maria Leila M. Doquenia, MD[1], Azlina Ahmad Annuar, PhD[4], Micol Avenali, MD[5,6], Soraya Bardien, PhD[7,8], Natascha Bahr[1], Melina Ellis, BSc[9,10], Caterina Galandra, MD[5,11], Thomas Gasser, MD, FANA, FEAN[12,13], Peter Heutink, PhD[12,13], Anastasia Illarionova, PhD[13], Yuliia Kanana, PhD[1], Ignacio J. Keller Sarmiento, MD[14], Kishore R. Kumar, MBBS, PhD, FRACP[10,15,16], Shen-Yang Lim, MD, FRACP[17], Harutyun Madoev, MS[1], Ignacio F. Mata, PhD[18], Niccolò E. Mencacci, MD, PhD[14], Mike A. Nalls, PhD[19,20], Shalini Padmanabhan, PhD[21], Cholpon Shambetova, MD[1], J Solle, MBA[22], Ai-Huey Tan, MD, PhD, FRCP[17], Joanne Trinh, PhD[1], Enza Maria Valente, MD[6,11], Andrew Singleton, PhD[20, 23], Cornelis Blauwendraat, PhD[20, 23], Katja Lohmann, PhD[1], Zih-Hua Fang, PhD[13], Christine Klein, MD[1] *and the Global Parkinson's Genetics Program (GP2)*

[1] Institute of Neurogenetics, University of Luebeck, Luebeck, Germany
[2] Department of Neurology, University Clinic Schleswig-Holstein, Luebeck, Germany
[3] Department of Neurology, University of Free State, Bloemfontein, South Africa
[4] Department of Biomedical Science, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
[5] Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy
[6] IRCCS Mondino Foundation, Pavia, Italy
[7] Division of Molecular Biology and Human Genetics, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
[8] South African Medical Research Council, Genomics of Brain Disorders Research Unit, Stellenbosch University, Cape Town, South Africa
[9] Northcott Neuroscience Laboratory, ANZAC Research Institute, Concord, New South Wales, Australia
[10] Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia
[11] Department of Molecular Medicine, University of Pavia, Pavia, Italy
[12] Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany
[13] German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany
[14] Ken and Ruth Davee Department of Neurology and Simpson Querrey Center for Neurogenetics, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA
[15] Translational Neurogenomics, Genomic and Inherited Disease Program, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia
[16] Molecular Medicine Laboratory and Neurology Department, Concord Repatriation General Hospital, The University of Sydney, Concord, New South Wales, Australia
[17] Division of Neurology, Department of Medicine, and the Mah Pooi Soo and Tan Chin Nam Centre for Parkinson's and Related Disorders, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
[18] Genomic Medicine Institute (GMI), Cleveland Clinic, Cleveland, OH, United States
[19] DataTecnica, Washington DC, USA
[20] Center for Alzheimer's and Related Dementias (CARD), National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA
[21] Discovery & Translational Research, The Michael J. Fox Foundation for Parkinson's Research, New York, New York, USA
[22] Department of Clinical Research, Michael J. Fox Foundation for Parkinson's Research, New York City, NY, USA
[23] Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA
*These authors have contributed equally to the work

Corresponding Author:
Christine Klein, MD
Institute of Neurogenetics, University of Lübeck
BMF, Building 67, Ratzeburger Allee 160
23538 Lübeck, Germany
and Department of Neurology, University Hospital Schleswig-Holstein, Lübeck
Ratzeburger Allee 160, 23538 Lübeck, Germany
Tel: +49-451-31018200

Email: christine.klein@uni-luebeck.de

Abstract

Until recently, about three-quarters of all monogenic Parkinson's disease (PD) studies were performed in European/White ancestry, thereby severely limiting our insights into genotype-phenotype relationships at global scale. The first systematic approach to embrace monogenic PD worldwide, the Michael J Fox Foundation Global Monogenic PD (MJFF GMPD) Project, contacted authors of publications reporting individuals carrying pathogenic variants in known PD causing genes. In contrast, the Global Parkinson's Genetics Program's (GP2) Monogenic Network took a different approach by targeting PD centers not yet represented in the medical literature. Here, we describe combining both efforts in a "merger project" resulting in a global monogenic PD cohort with build-up of a sustainable infrastructure to identify the multi-ancestry spectrum of monogenic PD and enable studies of factors modifying penetrance and expression of monogenic PD. This effort demonstrates the value of future research based on team science approaches to generate comprehensive and globally relevant results.

Introduction

Although monogenic forms of Parkinson's disease (PD) have been described worldwide, about three-quarters of all PD genetics studies have been performed in individuals of European/White ancestry [1], formally referred to as Caucasian, thereby severely limiting our current insight into genotype-phenotype relationships at a global, multiancestry scale and contributing further to healthcare and research disparities [2]. The first systematic approach to embrace monogenic PD worldwide, the Michael J. Fox Foundation Global Monogenic PD (MJFF GMPD) project, was built on the MDSGene Database that compiles published genotype-phenotype relationships for monogenic PD[1, 3-5] and other movement disorders (www.mdsgene.org). Corresponding authors of PD-related articles included in MDSGene were contacted and asked to provide additional information on previously reported or new information on recently identified individuals using an electronic case report form [1, 6]. Data were collected on almost 4,000 individuals from 89 centers in 41 countries, including affected and unaffected carriers of pathogenic variants in genes implicated in monogenic PD [1]. However, information remained scarce on the majority of ancestries other than European/White as well as on certain rare monogenic forms of PD, such as PD caused by the pathogenic *VP*S35 variant p.D620N. The Global Parkinson's Genetics Program (GP2; https://gp2.org) aims to close this gap by collecting samples and genetically testing individuals from previously established PD genetic research sites but also PD centers that did not yet perform genetic testing in their patients and/or have not yet participated in PD genetics research [7]. This enables PD genetic studies especially in yet mostly unexplored and therefore underrepresented populations [8]. The Monogenic Network of GP2 (GP2 MN) focuses on identifying novel monogenic causes of PD but also characterizing genotype-phenotype relations of known monogenic PD at a global scale [9]. Therefore, the present study builds on the efforts of the MJFF GMPD project, incorporating it into GP2 MN, and specifically extending the current global map of monogenic PD [8] to underrepresented sites and populations.

Methods

Recruitment of collaborating centers for the MJFF GMPD project was based on a systematic online approach to collect individual-level data on individuals with pathogenic variants in known PD genes (*SNCA, LRRK2, VPS35, PRKN, PINK1, PARK7*) and pathogenic or risk variants in *GBA1*[1]. This included clinical and demographic data to analyze genotype–phenotype

relationships [1]. In contrast, recruitment for the GP2 MN was more inclusive, and initially focused on individuals with an unsolved but suspected monogenic form of PD based on an early age at onset (AAO; ≤50 years of age) and/or a positive family history [9]. Potential collaborators were additionally identified through personal contacts, participation in PD consortia, and by advertising GP2 at congresses. Collaborators from both efforts were divided into three groups based on their involvement in both projects (Group 1), or only in the MJFF GMPD (Group 2) or the GP2 MN (Group 3).

Participants of the MJFF GMPD project received customized emails including relevant information about GP2 and an online survey gauging their interest in participating and their availability of DNA samples. Collaborators interested in joining GP2 were given standardized instructions for the onboarding process to GP2's MN [9]. Further, all collaborators previously involved in the MJFF GMPD project (Groups 1 and 2) were asked their permission to merge both efforts and transfer existing data and samples to the GP2 MN. Only centers with GP2 compliance approval until November 2023 are included in this manuscript. Compliance approval is based on an eligible consent form enabling international sample and data sharing and approval by the local Ethics Committee [9].

The assignment to underrepresented countries was based on the World Bank's classification on income status (https://data.worldbank.org/country/XO), classifying countries with a low and middle income as underrepresented.

Regardless of available genetic pre-screening, all samples from individuals with eligible clinical data that passed QC underwent genotyping with the NeuroBooster Array (NBA), including 1.9 million markers from the Illumina Global Diversity Array and more than 95,000 neurological disease-oriented and population-specific variants, including several hundred known variants in PD-related genes [10]. Genotyping did not include the analysis of copy number variants (CNV). Detected variants underwent a pathogenicity evaluation based on the criteria of the American College of Medical Genomics (ACMG) [11] using Franklin (https://franklin.genoox.com/clinical-db/home), the human genomic variant search engine VarSome [12], and MDSGene criteria (https://www.mdsgene.org/methods). Only variants interpreted as (likely) pathogenic or known PD risk variants were included. Additionally, variants in *LRRK2* were evaluated based on their impact on the LRRK2 kinase activity [13], while the *GBA1*-PD Browser (https://pdgenetics.shinyapps.io/gba1browser/) [14] was used to evaluate identified *GBA1*

variants. Efforts to perform short-read whole-genome sequencing including CNV analyses for this cohort are ongoing.

Percentages in the results section are given as valid percentages.

Data Sharing

Anonymized data will be shared by request from any qualified investigator.

Results

To date, 100 centers from 46 countries (Figure 1) are included in the GP2 MN. Of the 89 MJFF GMPD centers [1] contacted as part of the 'merger', 38 (42.7 %) joined the GP2 MN. Reasons for non-participation were diverse, e.g., including no response to the invitation to participate, delay or failure of the onboarding process due to bureaucratic hurdles (e.g., the consent form did not meet the legal requirements of GP2), or inability to provide DNA samples in addition to and clinical data.

Nineteen (19%) centers from 15 countries included in the GP2 MN were from underrepresented countries (Figure 1), eleven countries of which were not previously part of the MJFF GMPD project.

Thirty-four centers and the PDGene consortium (https://www.parkinson.org/advancing-research/our-research/pdgeneration) already submitted samples and clinical data to the GP2 MN for further analysis. For 66 centers, the onboarding process is still ongoing. To date, 5,374 DNA or blood samples were sent to the coordinating GP2 site in Luebeck, Germany, including 468 samples with pending clinical data. The vast majority (n=4,631) of these 4,906 ready-to-analyze samples are from affected individuals with PD/parkinsonism, and only a subset (n=275) is from unaffected relatives (Table 1) or unaffected mutation carriers. The median age at onset (AAO) was 49 (IQR: 41-61) years, and 55.7% had an early AAO (≤ 50 years; 17.5% missing data).

Genotyping of the GP2 MN cohort with the NBA identified (likely) pathogenic single nucleotide variants (SNVs) in known PD genes in 47 (1.8%) and (likely) pathogenic SNVs or PD risk variants in *GBA1* in 137 (5.2%) out of 2,648 individuals tested thus far; the genetic details are listed in Table 2. Heterozygous variants in dominant genes were identified in *LRRK2* (n=12) and *SNCA* (n=14), and one carrier of a pathogenic variant in *VPS35* was found. Sixteen carriers of

homozygous variants in *PINK1* and 4 homozygous variant carriers in *PRKN* were identified but no carriers of biallelic variants in *PARK7* (*DJ1*). Further, genotyping resulted in the identification of variants of uncertain significance (VUS) in known PD genes in 33 individuals, and 219 carriers of *LRRK2* risk variants previously associated with PD in Asian populations (Table 2).

Discussion

To date, 100 centers from 46 countries are included in the GP2 MN, 38% of which were previously recruited through the MJFF GMPD project[1]. An important reason for the non-participation of MJFF GMPD centers in GP MN was that the leading PI was no longer active, demonstrating the importance of dedicated researchers to drive projects such as the GP2 MN. Both projects followed different approaches when recruiting collaborators. The more inclusive but less 'systematic' approach of GP2's MN resulted in the inclusion of many underrepresented countries, some of which currently have few, if any, PD genetic testing efforts and publications in the literature and, therefore, were not detectable through the systematic literature-based approach of the MJFF GMPD project. Sixty-two centers not previously participating in the MJFF GMPD project were recruited for the GP2 MN, including 16 centers from underrepresented countries. However, the research infrastructure in these countries often posed a challenge to the onboarding process and required intensified efforts and support. Our goal is to overcome these bureaucratic and logistical hurdles to enable global representation of monogenic causes of PD. One way of doing this will be using and supporting established PD consortia in these areas, e.g., LARGE-PD (https://large-pd.org/).

So far, ~5,400 samples have been included in the GP2 MN, and ~3,900 individuals in the MJFF GMPD project. In the MJFF GMPD project, 3,185 affected and 703 unaffected mutation carriers were included[1]. Genetic testing of the GP2 MN cohort with the NBA has thus far identified (likely) pathogenic variants in 121 (including *GBA1* variant carriers), PD risk variants in *LRRK2* and *GBA1* in 252 and VUS in 33 out of 2,648 tested individuals. The low frequency of (likely) pathogenic variants is likely due to the initial selection criteria of the GP2 MN, which prioritized individuals with a negative genetic pre-screening, since a major aim of the MN is to discover new PD-related genes [9]. While GP2's MN initially focused on unsolved cases, the MJFF GMPD collected data and samples from individuals with known monogenic causes. Integrating the MJFF GMPD project into GP2 has widened the scope of GP2's MN. Merging both projects

will not only allow creating a sufficient infrastructure to identify the clinical spectrum across underrepresented ancestries of monogenic PD but also enable investigating factors modifying monogenic PD by identifying a large number of mutation carriers. Identifying patients with monogenic PD provides the basis for recruiting individuals with genetic PD/parkinsonism for future gene-specific clinical trials which is a dedicated aim of one of the GP2's special interest groups.

Our efforts of combining two large genetic PD research efforts underlines that the future of research should be based on team science approaches to combine data into even larger, standardized data sets to generate meaningful and globally relevant results [6]. A collaborative mindset is indispensable to share expertise internationally and to facilitate new research opportunities which will eventually enable the development of personalized therapies for individuals with PD.

Acknowledgment:

Data used in the preparation of this article were obtained from Global Parkinson's Genetics Program (GP2). GP2 is funded by the Aligning Science Across Parkinson's (ASAP) initiative and implemented by The Michael J. Fox Foundation for Parkinson's Research (https://gp2.org). For a complete list of GP2 members see https://gp2.org.

Funding Sources

This research was supported in part by the Intramural Research Program of the NIH, National Institute on Aging (NIA), National Institutes of Health, Department of Health and Human Services; project number ZO1 AG000534, as well as the National Institute of Neurological Disorders and Stroke.

GP2 is funded by the Aligning Science Across Parkinson's (ASAP) initiative and implemented by The Michael J. Fox Foundation for Parkinson's Research (https://gp2.org).

References

1. Vollstedt EJ, Schaake S, Lohmann K, et al. Embracing Monogenic Parkinson's Disease: The MJFF Global Genetic PD Cohort. Mov Disord 2023;38(2):286-303.
2. Schiess N, Cataldi R, Okun MS, et al. Six Action Steps to Address Global Disparities in Parkinson Disease: A World Health Organization Priority. JAMA neurology 2022;79(9):929-936.
3. Klein C, Hattori N, Marras C. MDSGene: Closing Data Gaps in Genotype-Phenotype Correlations of Monogenic Parkinson's Disease. J Parkinsons Dis 2018;8(s1):S25-S30.
4. Trinh J, Zeldenrust FMJ, Huang J, et al. Genotype-phenotype relations for the Parkinson's disease genes SNCA, LRRK2, VPS35: MDSGene systematic review. Mov Disord 2018;33(12):1857-1870.
5. Wittke C, Petkovic S, Dobricic V, et al. Genotype-Phenotype Relations for the Atypical Parkinsonism Genes: MDSGene Systematic Review. Mov Disord 2021;36(7):1499-1510.
6. Vollstedt EJ, Kasten M, Klein C, Group MGGPsDS. Using global team science to identify genetic parkinson's disease worldwide. Ann Neurol 2019;86(2):153-157.
7. Schumacher-Schuh AF, Bieger A, Okunoye O, et al. Underrepresented Populations in Parkinson's Genetics Research: Current Landscape and Future Directions. Mov Disord 2022;37(8):1593-1604.
8. Global Parkinson's Genetics P. GP2: The Global Parkinson's Genetics Program. Mov Disord 2021;36(4):842-851.
9. Lange LM, Avenali M, Ellis M, et al. Elucidating causative gene variants in hereditary Parkinson's disease in the Global Parkinson's Genetics Program (GP2). NPJ Parkinsons Dis 2023;9(1):100.
10. Bandres-Ciga S, Faghri F, Majounie E, et al. NeuroBooster Array: A Genome-Wide Genotyping Platform to Study Neurological Disorders Across Diverse Populations. medRxiv 2023.
11. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015;17(5):405-424.
12. Kopanos C, Tsiolkas V, Kouris A, et al. VarSome: the human genomic variant search engine. Bioinformatics 2019;35(11):1978-1980.
13. Kalogeropulou AF, Purlyte E, Tonelli F, et al. Impact of 100 LRRK2 variants linked to Parkinson's disease on kinase activity and microtubule binding. Biochem J 2022;479(17):1759-1783.
14. Parlar SC, Grenn FP, Kim JJ, Baluwendraat C, Gan-Or Z. Classification of GBA1 Variants in Parkinson's Disease: The GBA1-PD Browser. Mov Disord 2023;38(3):489-495.

Figure 1: World map of centers participating in the GP2 MN and the MJFF GMPD project



Colored are the countries from which one or more centers participated in the MJFF GMPD project and GP2 MN (blue) or only in GP2 MN (green). Colored in purple are new centers in underrepresented countries that were recruited based on the new approach of GP2 MN.

Blue: Argentina, Australia, Austria, Belgium, Canada, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Japan, Luxembourg, Malaysia, Netherlands, Norway, Poland, Portugal, Saudi Arabia, Singapore, Slovakia, South Africa, South Korea, Spain, Sweden, Taiwan, Thailand, Turkey, UK, USA

Green: Chile, Czechia, New Zealand, Switzerland

Purple: Bangladesh, Colombia, Indonesia, Iran, Mongolia, Nepal, Nigeria, Pakistan, Philippines, Sri Lanka, Tunisia

Table 1: Clinical Data of the 4,631 individuals with parkinsonism included in the Monogenic Network of the Global Parkinson´s Genetics Program (GP2).

	Available data	**Missing data** n (%)
Sex f = n/m =n	1899 (42.4%)/ 2582 (57.6%)	150 (3.2%)
Age median (IQR)	66 years (56-75 years)	295 (6.4%)
AAO median (IQR)	49 years (41-61 years)	809 (17.5%)
Ancestry	Native Hawaiian/Other Pacific Islander: 1 (<0.1%) American Indian/Alaska Native: 2 (<0.1%) Ashkenazi Jewish: 16 (0.5%) Black/African American: 26 (0.7%) Hispanic/Latino: 70 (2.0%) Arab: 104 (3.0%) White/European: 1471 (41.9%) Asian: 1762 (50.2%) Other: 58 (1.7%)	1121 (24.2%)
Family history of parkinsonism	Positive: 2103 (59.4%) Negative: 1436 (40.6%)	1092 (23.6%)
Consanguinity	Yes: 151 (7%) No: 2017 (93%)	2463 (53.2%)

AAO: Age at Onset; IQR: Interquartile range; PD: Parkinson's disease

Table 2. Genetic results from genotyping with the NeuroBooster Array (NBA).

Detected (likely) disease-causing variants (n = 47/2648; 1.8%)				
Gene	**Variant details**	**Pathogenicity Consensus[1]**	***LRRK2* kinase activity[2]**	**Affected carriers**
LRRK2	c.4321C>T; p.Arg1441Cys	Pathogenic	+	3
	c.4322G>A; p.Arg1441His	Pathogenic	+	1
	c.5281A>C ; p.Ser1761Arg	Likely pathogenic	+	1
	c.5385G>T ; p.Leu1795Phe	Pathogenic	+	2
	c.6055G>A; p.Gly2019Ser	Pathogenic	+	5
SNCA	c.157G>A; p.Ala53Thr	Pathogenic		13
	c.158C>A; p.Ala53Glu	Likely pathogenic		1
VPS35	c.1858G>A; p.Asp620Asn	Pathogenic		1
PINK1	c.774C>A; p.Tyr258*	Pathogenic		2
	c.1040T>C; p.Leu347Pro	Pathogenic		11
	c.1366C>T; p.Gln456*	Pathogenic		1
	c.1466T>C; p.Leu489Pro	Likely pathogenic		2
PRKN	c.758G>T; p.Cys253Phe	Likely pathogenic		1
	c.823C>T; p.Arg275Trp	Pathogenic		2
	c.850G>C; p.Gly284Arg	Likely pathogenic		1
Detected variants in *GBA1* (n = 137/2648; 5.2%)				
Gene	**Variant details**	**Pathogenicity Consensus[1]**	***GBA1 PD Browser*[2]**	**Affected carriers**
GBA1	c.254G>A; p.Gly85Glu	Pathogenic	Mild	1
	c.256C>T; p.Arg86*	Likely pathogenic	Severe	1
	c.260G>A; p.Arg87Gln	Pathogenic	NA	1
	c.437C>T; p.Ser146Leu	Likely pathogenic	Severe	2
	c.476G>A; p.Arg159Gln	Likely pathogenic	Severe	2
	c.535G>C; p.Asp179His	Likely pathogenic	Mild	1
	c.667T>C; p.Trp223Arg	Pathogenic	Severe	1
	c.681T>G; p.Asn227Lys	Likely pathogenic	Severe	3
	c.689T>G; p.Val230Gly	Pathogenic	NA	1
	c.719C>A; p.Pro240His	Likely pathogenic	Severe	1
	c.887G>A; p.Arg296Gln	Pathogenic	Severe	2
	c.896T>C; p.Ile299Thr	Likely pathogenic	NA	1
	c.928A>G; p.Ser310Gly	Likely pathogenic	Mild	2
	c.1093G>A; p.Glu365Lys	Risk variant	Risk variant	28
	c.1223C>T; p.Thr408Met	Risk variant	Risk variant	24
	c.1226A>G; p.Asn409Ser	Likely pathogenic	Mild	23
	c.1240G>T; p.Val414Leu	Pathogenic	Mild	1
	c.1246G>A; p.Gly416Ser	Pathogenic	Severe	1
	c.1271T>C; p.Leu424Pro	Likely pathogenic	NA	2
	c.1279G>A; p.Glu427Lys	Risk variant	Risk variant	1
	c.1279G>T; p.Glu427*	Likely pathogenic	NA	1
	c.1312G>T; p.Asp438Tyr	Pathogenic	NA	1
	c.1325T>C; p.Ile442Thr	Likely pathogenic	NA	1
	c.1342G>C; p.Asp448His	Pathogenic	Severe	29
	c.1495G>A; p.Val499Met	Likely pathogenic	Unknown	2
	c.1504C>T; p.Arg502Cys	Pathogenic	Severe	3
	c.1604G>A; p.Arg535His	Pathogenic	Mild	1
Detected variants of unknown significance (VUS) (n = 252/2648; 9.5%)				

Gene	Variant details	Pathogenicity Consensus	*LRRK2* kinase activity[2]	Affected carriers
LRRK2	c.458T>G; p.Leu153Trp	VUS	NA	1
	c.632C>T; p.Ala211Val	VUS	=	8
	c.872T>C; p.Val291Ala	VUS	NA	1
	c.2056C>T; p.Gln686*	VUS	NA	1
	c.2356A>T; p.Ile786Phe	VUS	NA	2
	c.2769G>C; p.Gln923His	VUS	NA	1
	c.3643G>A; p.Ala1215Thr	VUS	=	1
	c.3683G>C; p.Ser1228Thr	VUS	=	1
	c.4237G>A; p.Ala1413Thr	VUS	+	3
	c.4348G>A; p.Val1450Ile	VUS	=	2
	c.4883G>A; p.Arg1628His	PD risk variant	=	102
	c.5174G>A; p.Arg1725Gln	VUS	=	1
	c.5822G>A; p.Arg1941His	VUS	=	1
	c.6035T>C ; p.Ile2012Thr	VUS	+	2
	c.7067C>T; p.Thr2356Ile	VUS	=	1
	c.7153G>A; p.Gly2385Arg	PD risk variant	+	117
VPS35	c.2320C>A; p.Leu774Met	VUS		1
PINK1	c.1015G>A; p.Ala339Thr	VUS		1
PRKN	c.518C>T; p.Thr173Met	VUS		3
	c.1294A>G; p.Met432Val	VUS		2

VUS = variant of uncertain significance

[1] Pathogenicity scoring is based on a consensus using the Franklin by Genoox tool (https://franklin.genoox.com/about-franklin) that uses the criteria of the American College of Medical Genomics (ACMG)[11], the human genomic variant search engine VarSome [12], and the MDSGene criteria (https://www.mdsgene.org/methods).

[2] The evaluation of the kinase activity is based on previously published data [11]. The '+' symbol means this variant is enhancing the kinase activity, therefore supporting a (likely) pathogenic effect of this variant. The '=' symbol means that this variant does not affect the kinase activity, and 'NA' means that this information is not available because this variant has not yet been tested.

[3] The GBA1-PD Browser (https://pdgenetics.shinyapps.io/gba1browser/) was used to additionally evaluate identified *GBA1* variants.

Transcripts:

LRRK2: NM_198578.3; NP_940980.3
SNCA: NM_000345.3; NP_000336.1
VPS35: NM_018206.5; NP_060676.2
PINK1: NM_032409.2; NP_115785.1
PRKN: NM_004562.2; NP_004553.2
GBA1: NM_001005741.2; NP_001005741.1